This unique combination positions us at the forefront of developing the biomarkers and imaging technologies that will shape the future of personalised medicine.
Where Discovery Becomes Diagnostic.
Our mission is to establish Hull as a world‑leading centre for molecular imaging innovation by uniting cutting‑edge microscale synthesis technologies with a next‑generation cyclotron capable of producing low‑dose, small‑volume radiotracers.
This unique combination positions us at the forefront of developing the biomarkers and imaging technologies that will shape the future of personalised medicine.
Through a fully translational research programme integrated with a state‑of‑the‑art clinical imaging centre, we ensure that newly developed radiotracers can be manufactured to GMP standards and delivered rapidly and safely to patients.
By bridging discovery science with real‑world clinical application, we accelerate the journey from laboratory insight to improved diagnostic accuracy and patient outcomes. We pursue this mission by:
Expanding the use of PET‑CT to support patients with cardiological and neurological conditions.
Enhancing radiotherapy planning through advanced PET‑CT applications.
Developing and trialling novel radiotracers that illuminate disease processes with greater precision.
Pioneering dose‑on‑demand microfluidic technologies to enable more personalised, efficient, and accessible imaging.
Together, these commitments drive our ambition to transform diagnostic imaging, broaden access to advanced technologies, and improve health outcomes for communities locally, nationally, and globally.
Registered office: MIRC, Daisy Building, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ.
Registered company number 177823472
Call: 01482 461909